Prostrate and Breast Cancer Clinic

Prostrate and Breast Cancer: New Treatment Opions

Prostate cancer is today the most frequent malignant tumour in men, more frequent than lung cancer. It is the most commonly diagnosed cancer among Nigerian men but screening is not a common practice. A study carried out at University of Nigeria Teaching Hospital Enugu on urological cases showed that over a 13year period, urethral cancer-8 new cases, bladder cancers-103 new cases, ureteric cancers-7 new cases, kidney cancers-74 new cases, and prostate cancer-847 new cases.

Breast cancer constitutes a major public health [] globally with over 1 million new cases diagnosed annually resulting in over 400,000 annual deaths and about 4.4 million women living with the disease. The five year survival rates for breast cancer patients in the United States exceed [80%], in Nigeria it is a dismal 10%. It also affects one of eight women during their lives and is the most common cause of cancer mortality in women worldwide. It is responsible for 16% of all cancer [led] death in Nigeria.

Cancer should be likened to a home on the fire with about 3 or more rooms involved. If you call a fire brigade, you won’t want a single person to come with a small piston squatting water on the home. You will rather have 3-4 persons with powerful hose squatting water on the fire and if possible sprinklers from the ceiling helping as well. Cancer should be attacked in this manner, from several angles; conventional medicine, diet, detoxification, immune therapy, oxygen therapy, hyperthermia treatment and phytotherapy.

Good news for cancer of the prostate and breast patients, Life Hospital and Medical Spa Centre, which offers a holistic approach to your healthcare with a medical spa offering detoxification services such as colonic irrigation, hyperbaric oxygen therapy, far infrared sauna and therapeutic massage as well as specialist medical services in obstetrics and gynaecology, general practice, fertility and family planning clinics, cancer screening services and aesthetic clinic using detox and filler services is now collaborating with Prof. Ben L. Pieifer, M.D., PhD Professor and Director for Research and Development Aeskulap International, Lucerne Switzerland with respect to [an] integrative treatment approach to prostate and breast cancer.

Prof. Ben L. Pfeifer of Aeskulap International is combining conventional and complementary oncological treatments to create effective therapies for patients with metastatic and castration resistant prostate cancer and metastatic breast disease.

The integrative approach includes; basic complementary treatment measures such as dietary and life style changes, specific physical therapy and exercise programmes, psycho-oncology measures, hyperthermia and fever therapies, detoxifying treatments, enzyme therapy and specifically designed medical treatments utilizing various plant derived preparations (phytotherapy) tailored to individual patients.

Present day potential therapies such as radical prostatectomy, chemotherapy and radiation treatment only make sense as long as the cancer is confined to the prostate and metastasis has not developed. Unfortunately, these treatment methods lead in a high percentage of cases too unacceptable and permanent side effects e.g. erectile impotency in 60-100%, urinary inconvenience in 10-30% of patients, etc. Furthermore with regards to cure, the results of treatments by these invasive methods are still unsatisfactory; recurrence rates being between 20-30%.

There is presently still no cure for metastatic prostate cancer, castration resistant or hormone refractory prostate cancer and the testosterone ablation therapies such as orchidectomy or the administration of LHRH agonists and anti-androgens frequently only achieve short term tumour control (months to few years). Long term results are unsatisfactory and most prostate cancer patients become hormone refractory. At this stage there is often fast progression of the disease and metastasis develops and finally leads to death. Due especially to the unpleasant and often permanent side effects and the high rate of treatment failure, there is an ever increasing demand for complementary therapies by patients with prostate cancer and breast cancer. Often patients’ expectations of such treatments are too high. In particular, complementary treatments should not replace the potentially curative methods such as radical prostatectomy and radiation therapy. During the early stages of the disease when cancer growth is still confined to the prostate, complementary treatments in combination with standard therapy practices leads to good outcome. During the hormone refractory stage of the disease, however, complementary treatments have gained significance due to its low toxicity and better results.

These phytotherapy products have been shown to have the following effects; anti-inflammatory, anti-oxidative, support immune function, inhibit tumour growth, support normal cell differentiation, promote apoptosis, inhibit metastasis, inhibit formation of new blood vessels, reduce the likelihood of future mutations. Dietary measures are also important as 35-40% of all cancers are partly caused by poor or insufficient nutrition. Nutritional consultation and education therefore seems a sensible measure within the framework of primary and secondary prevention of cancer in general as well as in the specific example of complementary therapy for prostate cancer.

The so called “Gold-Standard” therapies for breast cancer include cancer removing surgery, usually combined with adjuvant chemotherapy, radiation treatment and /or endocrine therapy afterwards. Although this treatment sequence is effective for most of the patients, about 1/3 or more of the women with breast cancer will see their disease progress and become metastatic. If metastatic bone disease is present, then treatment with bisphosphonates or osteoclast inhibitors will often be added. These palliative treatment measures often help reduce tumour related complaints, however, their efficacy is rather limited, and therefore, the median survival time for metastatic breast cancer patients is reported in the range of 2-3 years in the best centre.

Experience shows that each patient with advanced and metastatic breast cancer responds differently, even if the disease history and the tumour markers are relatively similar. Over the years, Aeskulap International Centre has been able to develop a treatment algorithm which considers various patient data and allows to design a tailor made treatment program for each patient, including combinations of the following phytotherapy; Aeskulap-MCP, Aeskulap-CA-Statin, Aeskulap-Artemisinin among others. Sometimes TMAZ Zeolite is added in cases not responding well to the protocol. TMAZ is a powerful mineral supplement that boost immune function, helps prevent oxidation, detoxifies the body and balances pH.

For patients with a high tumour load, high CA-15-3 and aggressive tumour histology, we usually prescribe our phytotherapy-protocol in conjunction with palliative chemotherapy, radiation treatment, antibody therapy (Herceptin) and /or endocrine therapy. Our protocol medication does not negatively interfere with these standard treatment methods.

Special Cases

A 70year old patient in Switzerland became ill in autumn 2009. His symptoms were a therapy resistant cough. Lung x-rays showed multiple round lesions. Biopsy revealed PSA productive cells. Large core needle biopsy of the prostate confirmed the diagnosis of metastatic prostatic carcinoma. Initially, the patient refused any treatment due to the very advanced stage. However, when his PSA increased to almost 1000ng/ml and in the meantime bone metastatic were revealed, the patient decided to proceed with the above described phytotherapy in combination with the anti-oxidative and immune supportive therapy. During this process his PSA values dropped to <0.1ng/ml within 10months and even now 4 years after commencing therapy have remained constant.

In Abuja, a 79year old patient was diagnosed with metastatic prostate cancer in 2011. His symptoms were bone pain and frequency in urinating. Prostate biopsy confirmed the prostate cancer. He has received LHRH analogues, chemotherapy and radiotherapy. His metastatic prostatic cancer became hormone refractory and LHRH analogues were discontinued in 2012 and so was chemotherapy in April 2015 on patients choice due to the unpleasant effects. He presented to us in May 2015 with a PSA of 1228ng/ml, serious bone pain and was commenced on the above phytotherapy, zometa, diet therapy; detoxification; Near and Far Sauna, Colonic Irrigation and Hyperbaric Oxygen Therapy. Six weeks after the commencement of the above, his bone pain has resolved and PSA value is 215ng/ml with an improved quality of life.

In Abuja, a 54year old patient was diagnosed with metastatic prostate cancer in the USA in 2013 His symptoms were that of gross haematuria and retention. A prostate biopsy confirmed an adeno carcinoma. His PSA on presentation in the USA, was 417ng/ml, he has been receiving several injection, of LHRH analogues with fluctuating PSA values. Due to metastasis to bone, he started experiencing bone pain. He presented to us in May 2015 with the bone pain, PSA value of 130ng/ml and was commenced on phytotherapy, LHRH analogues, zometa and diet therapy, due to financial constraints wasn’t able to commence detoxification. After 4 weeks of commencement, his PSA values has dropped to 12.5ng/ml, resolved bone pains and improved quality of life.

...from the doctor

Patient consultations and management are made in conjunction with Prof. Pfeifer and Auskulap International, personal consultations with Prof. Ben L. Pfeifer can also be arranged via Skype conference calls or in person in Switzerland.
Auskulap International and Prof. Ben L. Pfeifer are located in Lucerne Switzerland; hence in its efforts to reach a wider population, Life Hospital and Medical Spa Centre serves as its liaison in Nigeria as the two organization have a memorandum of understanding.

---